Cargando…

Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review

Prostate cancer (PCa) is a serious threat to the health of men all over the world. The progression of PCa varies greatly among different individuals. In clinical practice, some patients often progress to advanced PCa. Therefore, accurate imaging for diagnosis and staging of PCa is particularly impor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Li, Zhang, Zhengchao, Wang, Ting, Yuan, Leihong, Sun, Xiaoke, Su, Pengxiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505927/ https://www.ncbi.nlm.nih.gov/pubmed/37727211 http://dx.doi.org/10.3389/fonc.2023.1179595

Ejemplares similares

PSMA-targeted therapy for non-prostate cancers
por: Wang, Jarey H., et al.
Publicado: (2023)

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis
por: Hupe, Marie Christine, et al.
Publicado: (2018)

PSMA PET in Imaging Prostate Cancer
por: Tsechelidis, Ioannis, et al.
Publicado: (2022)

Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
por: Szponar, Paweł, et al.
Publicado: (2023)

PSMA ligands for diagnosis and therapy of prostate cancer
por: Haberkorn, Uwe
Publicado: (2014)

Targeted Prostate Biopsy Using (68)Gallium PSMA-PET/CT for Image Guidance
por: Simopoulos, Demetrios N., et al.
Publicado: (2017)

Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective
por: Ng, Thomas S. C., et al.
Publicado: (2021)

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer
por: Cereser, Lorenzo, et al.
Publicado: (2023)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
por: Combes, Alexander D., et al.
Publicado: (2022)

PSMA PET imaging in the diagnosis and management of prostate cancer
por: Houshmand, Sina, et al.
Publicado: (2023)

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer
por: Luining, Wietske I., et al.
Publicado: (2022)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

Application of Multiple Ultrasonic Techniques in the Diagnosis of Prostate Cancer
por: Liu, Yushan, et al.
Publicado: (2022)

Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging
por: Topoozian, Mark, et al.
Publicado: (2023)

PSMA-targeted [(18)F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework
por: Reyes, Diane K., et al.
Publicado: (2019)

Editorial: Magnetic resonance imaging applications for the diagnosis of prostate cancer
por: Preisser, Felix, et al.
Publicado: (2023)

Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
por: Su, Pengxiao, et al.
Publicado: (2023)

Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge
por: Vetrone, Luigia, et al.
Publicado: (2023)

Application Value of Radiomic Nomogram in the Differential Diagnosis of Prostate Cancer and Hyperplasia
por: Gui, Shaogao, et al.
Publicado: (2022)

Editorial: Exploring the Potential of PSMA-PET Imaging on Personalized Prostate Cancer Treatment
por: Ilhan, Harun, et al.
Publicado: (2022)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

(177)Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry
por: Abouzayed, Ayman, et al.
Publicado: (2023)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [(18)F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
por: Shenderov, Eugene, et al.
Publicado: (2017)

New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen
por: Cimadamore, Alessia, et al.
Publicado: (2018)

PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis
por: Bravaccini, Sara, et al.
Publicado: (2018)

Case Report: Long-term complete response to PSMA-targeted radioligand therapy and abiraterone in a metastatic prostate cancer patient
por: Parker, David, et al.
Publicado: (2023)

GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches
por: Verhoeven, Marjolein, et al.
Publicado: (2023)

Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer
por: Alberto, Matthew, et al.
Publicado: (2022)

The efficacy of (99m)Tc-HYNIC-PSMA SPECT/CT in detecting primary lesions and metastasis in newly diagnosed prostate cancer
por: Wang, Taisong, et al.
Publicado: (2023)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

Automated diagnosis of pancreatic mucinous and serous cystic neoplasms with modality-fusion deep neural network using multi-modality MRIs
por: Zhang, Gong, et al.
Publicado: (2023)

Low-Dose 68 Ga-PSMA Prostate PET/MRI Imaging Using Deep Learning Based on MRI Priors
por: Deng, Fuquan, et al.
Publicado: (2022)

Predictive and prognostic potential of pretreatment (68)Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
por: Assadi, Majid, et al.
Publicado: (2022)

Facile Synthesis of Holmium-Based Nanoparticles as a CT and MRI Dual-Modal Imaging for Cancer Diagnosis
por: Zhang, Tianqi, et al.
Publicado: (2021)

Efficacy and Safety of (225)Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Ma, Jiao, et al.
Publicado: (2022)

Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer
por: Dal Pra, Alan, et al.
Publicado: (2016)

Editorial: Cutting-edge liver surgery-based modalities for diagnosis and treatment of liver tumors
por: Hu, Haoran, et al.
Publicado: (2023)

Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of (225)Ac-PSMA (Prostate-Specific Membrane Antigen)
por: Belli, Maria Luisa, et al.
Publicado: (2020)

Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors
por: Ngen, Ethel J., et al.
Publicado: (2021)

The (18)F-PSMA-1007 PET/CT performance on metastasis status and therapy assessment in oligo-metastasis prostate cancer
por: Wang, Zhuonan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g09u51u0fosg43eekpdd7tn2t3